Jakubowitz Law
Business Minds. Legal Insight.

We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.

Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Frequency Therapeutics, Inc. (FREQ)

Frequency Therapeutics is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: the Company’s Phase 2a trial results failed to live up to the Company’s expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322’s potential. These statements materially misled the market and artificially inflated the value of Frequency’s common stock.

If you incurred a loss on FREQ stocks purchased between November 16, 2020 and March 22, 2021, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the District of Massachusetts, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until August 2, 2021 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Fill out the form below to be contacted by a representative of Jakubowitz Law.

Loss Submission Form

See If you Qualify for Monetary Reward

Jakubowitz Law does not share your information with others.
There is no cost or obligation for you to submit

This submission does not create an attorney-client relationship.
If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss
whether to establish an attorney-client relationship.